First-line bortezomib benefits patients with multiple myeloma

Meletios A Dimopoulos, Katja Weisel, Philippe Moreau, Larry D. Anderson, Darrell White, Jesús F. San Miguel, Pieter Sonneveld, Monika Engelhardt, Matthew Jenner, Alessandro Corso, Jan Dürig, Michel Pavic, Morten Salomo, Eva Casalz, Ruiyun Jiang, Shankar Srinivasan, Tuong Vi Nguyen, Amine Bensmaine, Teresa Peluso, Paul G. Richardson

Article2025

Linvoseltamab (LINVO) + bortezomib (BTZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): First results from the LINKER-MM2 trial.

Paula Rodríguez‐Otero, Sosana Delimpasi, Albert Oriol, Meletios A Dimopoulos, Xavier P. Leleu, Salomon Manier, Carmen Martínez‐Chamorro, Rajshekhar Chakraborty, Sam Rubinstein, Anna Sureda, Marta Sonia González, Jean‐Marie Michot, Aurora Breazna, James Drew, Anita Boyapati, Sheila Masinde, Glenn S. Kroog, Shawn Sarkaria, Joaquín Martínez‐López